478841-07-5

Upstream product

• 14660-52-7 ethyl 5-bromovalerate 
• 6436-90-4 ethyl 2-(benzylamino)acetate 
• 100-46-9 benzylamine 

Downstream Products

• 478841-08-6 ethyl 1-benzyl-3-oxoazepane-2-carboxylate 
• 478841-09-7 1-benzyl-3-oxoazacycloheptane-4-carboxylic acid ethyl ester 
• 146407-32-1 1-benzylazepan-3-one 
• 870842-23-2 3-oxoazepane-1-carboxylic acid tert-butyl ester 
• 478841-10-0 1,1-dimethylethyl 3-hydroxy-hexahydro-1H-azepine-1-carboxylate 
• 148473-84-1 1-benzylazepan-3-ol 

Relevant academic research and scientific papers

Aza-seven-membered ring inhibitor as well as preparation method and application thereof

The invention relates to an aza-seven-membered ring inhibitor as well as a preparation method and application thereof. Specifically, the compound has a structure as shown in a formula (I), the invention further discloses a preparation method of the compou

Novel KRAS G12C protein inhibitor as well as preparation method and application thereof

The invention belongs to the field of medicinal chemistry, and relates to a novel KRAS G12C protein inhibitor as well as a preparation method and application thereof. Specifically, the invention provides a compound with a structure as shown in a formula I, and the compound can be used as an efficient KRAS G12C protein inhibitor and has various pharmacological activities of resisting tumors, proliferative diseases, inflammation, autoimmune diseases and the like.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to inhibitors of one or more isoforms of RAS, such as inhibitors of one or more of KRAS, HRAS and NRAS, or mutants thereof, such as G12D, G12V, G13D or G12C mutants thereof. Therapeutic methods of treating conditions and dis

BTK INHIBITOR

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).